Moreover, a recent report showed that high expression levels of miR-210 in plasma are associated with the presence of tumor in patients with breast cancer and with trastuzumab resistance in patients with HER2-positive breast cancer (25). The gene discussed is ERBB2; the disease is breast carcinoma.